Neurofibromatosis Type 1 Clinical Trial
— COGTRAINOfficial title:
Multimodal Intervention Trial for Cognitive Deficits in Neurofibromatosis Type 1: Efficacy of Computerized Cognitive Training and Stimulant Medication
NCT number | NCT02944032 |
Other study ID # | 00007343 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 2016 |
Est. completion date | September 27, 2021 |
Verified date | March 2022 |
Source | Children's National Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of the study is to assess the efficacy of a home-based, computerized cognitive training (CT) program, called CogmedRM, targeted to improve working memory in children with NF1 and working memory difficulties. This is a Phase II randomized parallel group controlled clinical trial comparing two interventions on cognitive outcomes. Participants will be stratified by stimulant medication use and randomized equally between the two interventions within stratum. Participants will be in the study for to 11 weeks.
Status | Completed |
Enrollment | 103 |
Est. completion date | September 27, 2021 |
Est. primary completion date | September 27, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 8 Years to 16 Years |
Eligibility | Inclusion Criteria: 1. 8-16 years old at time of screening 2. NF1 Diagnosis based on National Institute of Health (NIH) criteria 3. Has an identified caregiver who is willing and able to oversee the training practice during the intervention period 4. Has access to a telephone and phone number where they can be reached 5. Both patient and caregiver have reading, speaking, and listening comprehension of English 6. Treated with a stable dose of stimulant medication for at least the last 30 days and not planning to change the dose during study participation or receiving no stimulant medications for at least the last 30 days and not planning to initiate a trial of stimulant medications for the duration of the study. 7. >1 Standard Deviation (SD) below the mean on the WISC-V-Integrated Spatial Span Backwards task or a Spatial Span Backwards score >1 SD below the participant's estimated IQ. Exclusion Criteria: 1. Full scale IQ<70, as estimated by WASI-II (Block Design, Vocabulary, Matrix Reasoning, Similarities). Note: In cases where there is a statistically significant difference between verbal IQ and performance IQ (.05 level as determined by the WASI-II manual), participants will be eligible if at least one of these quotients is 70 or above 2. Current treatment for intracranial lesions, progressive tumors as per MRI evaluation or treatment with chemotherapy within the past 6 months 3. A motor, visual, or auditory handicap that prevents computer use |
Country | Name | City | State |
---|---|---|---|
United States | Children's National Health System | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Kristina Hardy | Children's Hospital Los Angeles, Children's National Health System, Royal Children's Hospital, Sydney Children's Hospitals Network |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in CogState One-back subtest | Computerized task of working memory | From baseline to end of training, up to 11 weeks | |
Secondary | Change in Attention Deficit Hyperactive Disorder- Rating Scale | Parent-completed rating scale | From baseline to end of training, up to 11 weeks | |
Secondary | Change in Wechsler Intelligence Scale for Children-Fifth Edition-Integrated Spatial Span Backward | Visual-spatial working memory task | From baseline to end of training, up to 11 weeks | |
Secondary | Change in Wechsler Intelligence Scale for Children-Fifth Edition-Integrated Digit Span Backward | Auditory working memory task | From baseline to end of training, up to 11 weeks | |
Secondary | CogState One-card Learning | Computerized attention and executive functioning tasks | From baseline to end of training, up to 11 weeks | |
Secondary | Change in Behavior Rating Inventory of Executive Functioning (BRIEF) Working Memory Index | Parent-completed questionnaire | From baseline to end of training, up to 11 weeks | |
Secondary | Change in Test of Word Reading Efficiency-Second Edition (TOWRE-2) Scores | Child-completed reading task | From baseline to end of training, up to 11 weeks | |
Secondary | Change in Test of Everyday Reading Comprehension (TERC) Scores | Child-completed reading task | From baseline to end of training, up to 11 weeks | |
Secondary | Change in Behavior Rating Inventory of Executive Functioning (BRIEF) Metacognition Index | Parent-completed questionnaire | From baseline to end of training, up to 11 weeks | |
Secondary | CogState Groton Maze Learning Task | Computerized task of executive functioning | From baseline to end of training, up to 11 weeks | |
Secondary | Change in Wechsler Intelligence Scale for Children-Fifth Edition-Integrated Letter-Number Sequencing | Auditory working memory task | From baseline to end of training, up to 11 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03190915 -
Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
|
Phase 2 | |
Completed |
NCT03326388 -
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
|
Phase 1/Phase 2 | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Active, not recruiting |
NCT01362803 -
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01218139 -
Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients
|
N/A | |
Recruiting |
NCT05149469 -
Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
|
||
Not yet recruiting |
NCT02505412 -
Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients
|
N/A | |
Terminated |
NCT02256124 -
Effect of Lamotrigine on Cognition in NF1
|
Phase 2/Phase 3 | |
Completed |
NCT01707836 -
Neurofibromatosis Type 1 Brain Tumor Genetic Risk
|
N/A | |
Active, not recruiting |
NCT01218152 -
Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs
|
N/A | |
Recruiting |
NCT03975829 -
Pediatric Long-Term Follow-up and Rollover Study
|
Phase 4 | |
Recruiting |
NCT05186870 -
Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
|
||
Active, not recruiting |
NCT03231306 -
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas
|
Phase 2 | |
Withdrawn |
NCT03332030 -
Stem Cells in NF1 Patients With Tumors of the Central Nervous System
|
||
Recruiting |
NCT02964884 -
Interventions for Reading Disabilities in NF1
|
Phase 2 | |
Recruiting |
NCT05388370 -
PASS of Paediatric Patients Initiating Selumetinib
|
||
Recruiting |
NCT02777775 -
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
|
||
Completed |
NCT01851135 -
Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1
|
N/A | |
Completed |
NCT01410006 -
Neurofibromatosis Type 1 Patient Registry
|
N/A | |
Active, not recruiting |
NCT00326872 -
AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
|
Phase 2 |